AcouSort sells AcouWash system to Pharmacolog
AcouSort has sold an AcouWash system to Uppsala-based Pharmacolog AB. The deal has its origins in the Letter of Intent that the companies announced in May 2021 and follows a successful evaluation process of AcouSort’s blood-plasma separation technology as well as for the business potential of the application. The total revenues generated at AcouSort as part of the project is EUR 41,000 in 2022.
In May 2021 AcouSort AB and Uppsala-based Pharmacolog AB signed a Letter of Intent concerning a long-term collaboration focused on investigating the potential of integrating AcouSort’s technology in Pharmacolog’s products. The aim was that the collaboration should result in the development of a novel product for determination of antibiotic concentration in blood from critically ill patients.
– We are very excited for this collaboration and we see great potential in combining our core technology with Pharmacolog’s technology for spectrophotometric analysis of blood plasma samples to benefit severely ill patients. This deal has been made after a successful evaluation of AcouSort’s blood-plasma separation technology as well as for the business potential of the application. We can also see that more and more life science companies are discovering that our technology can solve some of their core problems, allowing them to develop next generation of point-of-care devices and analytical instruments, which bodes well for the future, says AcouSort’s CEO Torsten Freltoft.
– At Pharmacolog we look very much forward to this next phase of the collaboration with AcouSort. By introducing the AcouWash technology for sample preparation, we realized that the test results became very positive and showed that AcouSort’s acoustic separation technology provides a better and more stable quality of the plasma compared to other separation methods, says Pharmacolog’s CEO Mats Högberg.
The next phase in this project includes measurements performed in a clinical environment at hospitals in Malmö and Uppsala where blood from patients will be tested. AcouSort’s contribution will be developing a dedicated blood-plasma separation version of the AcouWash system that may be operated by hospital staff. Pharmacolog’s system will be used at their head-quarter in Uppsala as well as at the hospital in Uppsala. In addition, a second AcouWash system will be temporarily placed at the Malmö hospital during the study.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.